Euromed Pharma’s Post

🌟𝗪𝗵𝗮𝘁 𝗮 𝗱𝗮𝘆! Having concluded our 𝟮𝗻𝗱 𝗔𝗻𝗻𝘂𝗮𝗹 𝗕𝗼𝘀𝘁𝗼𝗻 𝗥𝗮𝗱𝗶𝗼𝗻𝘂𝗰𝗹𝗶𝗱𝗲 𝗧𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗙𝗼𝗿𝘂𝗺, we've got to say it's been another event 𝗳𝘂𝗹𝗹 𝗼𝗳 𝘁𝗵𝗼𝘂𝗴𝗵𝘁-𝗽𝗿𝗼𝘃𝗼𝗸𝗶𝗻𝗴 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 💡 Building on the 𝗺𝗼𝗺𝗲𝗻𝘁𝘂𝗺 𝗼𝗳 𝗹𝗮𝘀𝘁 𝘆𝗲𝗮𝗿, this year's forum brought together an even greater number of 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗲𝘅𝗽𝗲𝗿𝘁𝘀, 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀, 𝗮𝗻𝗱 𝗸𝗲𝘆 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗽𝗹𝗮𝘆𝗲𝗿𝘀 to discuss the latest 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 in the rapidly evolving 𝗿𝗮𝗱𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰𝘀 market. 📈 💬 “Numerous announcements prove that the radiopharmaceutical 𝗺𝗮𝗿𝗸𝗲𝘁 𝗶𝘀 𝗺𝗼𝗿𝗲 𝗱𝘆𝗻𝗮𝗺𝗶𝗰 𝗮𝗻𝗱 𝘃𝗶𝗯𝗿𝗮𝗻𝘁 than ever before. We were 𝗵𝗼𝗻𝗼𝗿𝗲𝗱 to host the second Radionuclide Theranostics Forum in Boston in such 𝗲𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝘁𝗶𝗺𝗲𝘀,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. “This year's discussions focused on these 𝗻𝗲𝘄 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀, while building on the foundations of 2023. Always having in mind future market challenges, the ideas and partnerships that emerged here will 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝘄𝗼𝗿𝗹𝗱𝘄𝗶𝗱𝗲 in the long term.” The event featured 𝘁𝗮𝗹𝗸𝘀 𝗯𝘆 𝗼𝘃𝗲𝗿 𝗮 𝗱𝗼𝘇𝗲𝗻 international experts and executives, with dynamic panel discussions. The forum has solidified its reputation as a 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗳𝗼𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 and knowledge exchange in radiotheranostics. 🧠 📅 𝗠𝗮𝗿𝗸 𝘆𝗼𝘂𝗿 𝗰𝗮𝗹𝗲𝗻𝗱𝗮𝗿𝘀 for next year: The 𝟯𝗿𝗱 𝗲𝗱𝗶𝘁𝗶𝗼𝗻 of the Forum will be held on 𝗠𝗮𝘆 𝟮𝟵, 𝟮𝟬𝟮𝟱. Eckert & Ziegler remains committed to 𝗳𝗼𝘀𝘁𝗲𝗿𝗶𝗻𝗴 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 and advancing radiotheranostics to 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀. 💙 𝗛𝘂𝗴𝗲 𝘁𝗵𝗮𝗻𝗸𝘀 go out to Ken Herrmann and our sponsors and supporters Solomon Partners, SOFIE, Morrison Foerster and the German-American Business Council of Boston, Inc. as well as all the contributors: BAMF Health, Lantheus, Novartis, SHINE Technologies, ARTBIO, AdvanCell, Molecular Partners, Bayer, Aktis Oncology, and Ariceum Therapeutics 🔗 A full version of the press release can be accessed by using the link in the comments ⬇️ #ContributingToSavingLives #Theranostics #Radiopharmaceuticals #NuclearMedicine #PrecisionMedicine

📅Save the Date for the Fierce Biotech Summit 2024, where industry leaders discuss the evolving biotech landscape, including AI in drug development, dealmaking strategies, and oncology innovations. Join us on September 30 - October 1, 2024, in Boston, MA. Connect with seasoned executives and explore the future of biotech. Brought to you by the editors behind Fierce Biotech, this three-day event will cover the use of AI in drug development, unique dealmaking strategies, the latest innovations in oncology and much more. Interested in attending? Join our mailing list to stay updated on when registration will be open✅https://lnkd.in/dmcFa2Sa #FierceBiotechSummit #BiotechInnovation #SaveTheDate

We are thrilled to share that our President and CEO, Dr Anthony G Johnson, along with our Chief Business Officer, Sean A. MacDonald, will be attending three prestigious investor, partnering and healthcare industry conferences: Bloom Burton & Co. Healthcare Investor Conference hosted by Bloom Burton & Co. LSX World Congress organized by LSX - partnering for Life Science eXecutives BioEquity Europe organized by teams from BioCentury Inc. and EBD Group What’s in the spotlight? This is a unique opportunity to gain insights into our latest advancements in precision #immunotherapy. Our leaders will be showcasing the promising clinical development prospects of our pipeline, which is dedicated exclusively to GPCRs in #immunooncology. They will be focusing on our key drug candidates: DT-7012, an anti-CCR8 Treg-depleting monoclonal antibody in preclinical development DT-9045, a small molecule PAR2 receptor antagonist, also in preclinical development DT-9081, currently in Phase I clinical trials, this small molecule targets the EP4 receptor Don’t miss this chance to meet our passionate and success-driven leaders face-to-face. They are eager to discuss strategies that will further solidify our position as the leading #GPCR company in immuno-oncology. Stay tuned for official updates and highlights from each event and reach out if you would like to schedule a meeting. For more information, please follow the link in comments. #drugdevelopment #precisionmedicine

📅Save the Date for the Fierce Biotech Summit 2024, where industry leaders discuss the evolving biotech landscape, including AI in drug development, dealmaking strategies, and oncology innovations. Join us on September 30 - October 1, 2024, in Boston, MA. Connect with seasoned executives and explore the future of biotech. Brought to you by the editors behind Fierce Biotech, this three-day event will cover the use of AI in drug development, unique dealmaking strategies, the latest innovations in oncology and much more. Interested in attending? Join our mailing list to stay updated on when registration will be open✅https://lnkd.in/dmcFa2Sa #FierceBiotechSummit #BiotechInnovation #SaveTheDate

AESARA Europe can help you: 👩🏫 Train your colleagues on the EU HTA & JCA 🏗 Build the processes, capabilities & governance structures for this new HTA at the EU level 📑 Execute and submit a JCA dossier. Get in touch to ask how we can help you. #EUHTAR #EU #JCA #HTA

Join ZS’s Romain Bonnot, Malik Kaman and Parul Mahajan at BIO 2024 on June 4 for their panel, “Future of biopharma innovation: Unleashing the potential of emerging therapeutic modalities in oncology and beyond.” They’ll discuss the latest trends in the pharma product landscape, specifically new emerging modalities that have the potential to address areas of high unmet need and improve patient outcomes. Register here: #BIOInternational #BIO2024 #ZSatBIO

Join ZS’s Romain Bonnot, Malik Kaman and Parul Mahajan at BIO 2024 on June 4 for their panel, “Future of biopharma innovation: Unleashing the potential of emerging therapeutic modalities in oncology and beyond.” They’ll discuss the latest trends in the pharma product landscape, specifically new emerging modalities that have the potential to address areas of high unmet need and improve patient outcomes. Register here: #BIOInternational #BIO2024 #ZSatBIO

The oncology landscape is evolving rapidly—what’s driving these shifting trends? The recent changes in FDA oncology drug approvals have sparked important questions—what’s driving these industry trends, and how are they shaping today’s investment climate? In this article, we interviewed several of our clients to gain their insights on the current oncology landscape and the drivers shaping its future. Read the full article to discover what these changes mean for the future of oncology. https://lnkd.in/ds4h8wjP #Oncology #Biotech #FDA #FDAapprovals #CancerResearch ======== About Theoria Creative Theoria Creative is a marketing firm, enabling life sciences companies to clearly communicate complex science to investors, partners, and peers. We develop communication strategy, messaging, positioning, and prepare a set of illustrated materials that help companies clearly and succinctly articulate their value at high stakes meetings. ========

Join ZS’s Romain Bonnot, Malik Kaman and Parul Mahajan at BIO 2024 on June 4 for their panel, “Future of biopharma innovation: Unleashing the potential of emerging therapeutic modalities in oncology and beyond.” They’ll discuss the latest trends in the pharma product landscape, specifically new emerging modalities that have the potential to address areas of high unmet need and improve patient outcomes. Register here: #BIOInternational #BIO2024 #ZSatBIO

Join ZS’s Romain Bonnot, Malik Kaman and Parul Mahajan at BIO 2024 on June 4 for their panel, “Future of biopharma innovation: Unleashing the potential of emerging therapeutic modalities in oncology and beyond.” They’ll discuss the latest trends in the pharma product landscape, specifically new emerging modalities that have the potential to address areas of high unmet need and improve patient outcomes. Register here: #BIOInternational #BIO2024 #ZSatBIO